论文部分内容阅读
目的 探讨MTT体外药敏试验指导晚期肺癌并胸水的胸腔化疗的价值。方法 138例晚期肺癌并胸水的病人中 69例在胸腔化疗前接受了MTT体外药敏试验。其中MTT敏感组 58例 ,根据药敏结果指导胸腔化疗 ;MTT耐药组 11例和对照组 69例则凭经验胸腔化疗。结果 MTT敏感组有效率为 77.6% ( 4 5/58) ,MTT耐药组和对照组分别为 0 ( 0 / 11)及 4 4 .9% ( 31/ 69) ,差异有显著意义。敏感组与对照组在不同治疗阶段、化疗药物的小组比较中有显著性差异。本研究体外药敏和体内疗效的总符合率为 81.2 % [( 4 5+11) /69]。结论 MTT体外药敏试验指导肺癌并胸水的胸腔化疗是可行的
Objective To investigate the value of MTT in vitro susceptibility testing in the treatment of advanced lung cancer with pleural effusion. Methods 69 patients with advanced lung cancer and pleural effusion received MTT in vitro susceptibility test before thoracic cavity chemotherapy. 58 patients in the MTT-sensitive group were guided by thoracic cavity chemotherapy based on drug sensitivity; 11 patients in the MTT-resistance group and 69 in the control group received chemo-experience chemotherapy. Results The effective rate of MTT sensitive group was 77.6% (45/58). The MTT resistance group and control group were 0 (0/11) and 44.9% (31/69) respectively. The difference was significant. There was a significant difference between the sensitive group and the control group in the different treatment stages and the chemotherapy group. The total coincidence rate of in vitro susceptibility and in vivo efficacy in this study was 81.2% [( 4 5+11)/69]. Conclusion MTT in vitro susceptibility testing is feasible for thoracic chemotherapy of lung cancer and pleural effusion